The present application relates to a sulfonate-based compound and a method for preparing the same.

The present application relates to a sulfonate-based compound and a method for preparing the same.

The present application relates to a sulfonate-based compound and a method for preparing the same.

The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.

The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.

This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).

This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).

The present disclosure relates to a crosslinking ligand, a method for patterning a nanoparticle layer, a quantum dot light-emitting device, and a display device. The crosslinking ligand includes: at least two coordinating groups, at least one photosensitive degradation group and at least one thermosensitive crosslinking group, both of which are connected between the coordinating groups. The method for patterning the nanoparticle layer includes: forming a nanoparticle layer on a substrate; attaching a solution containing the crosslinking ligand to the substrate, to allow the crosslinking ligand to form a crosslinking between nanoparticles; performing a light irradiation treatment on a preset region of the substrate; removing the nanoparticles in the preset region; and performing a heat treatment on the substrate. The present disclosure does not need to design the structure of the ligand of the nanoparticles, and can form a nanoparticle layer with high resolution, simple process and high realizability.

The present disclosure relates to a crosslinking ligand, a method for patterning a nanoparticle layer, a quantum dot light-emitting device, and a display device. The crosslinking ligand includes: at least two coordinating groups, at least one photosensitive degradation group and at least one thermosensitive crosslinking group, both of which are connected between the coordinating groups. The method for patterning the nanoparticle layer includes: forming a nanoparticle layer on a substrate; attaching a solution containing the crosslinking ligand to the substrate, to allow the crosslinking ligand to form a crosslinking between nanoparticles; performing a light irradiation treatment on a preset region of the substrate; removing the nanoparticles in the preset region; and performing a heat treatment on the substrate. The present disclosure does not need to design the structure of the ligand of the nanoparticles, and can form a nanoparticle layer with high resolution, simple process and high realizability.

This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).